The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
RM

r.mcalister

TL3 Regular · Glasgow, UK

Retired process engineer. Interested in variability: between batches, between people, between weeks.

Joined 30 September 2024 · last posted 6d

132Posts here
1Topics
1Solutions
905Likes received
490Likes given
23Badges
199Days visited
2.9kPosts read

Most-liked posts

  • A plateau that disappeared when I changed how I measured Replied, post #26 · Outcomes › Progress reports · 24 Mar 2026 · 32 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
  • Second pass at: Historical amylin analogues and what happened to them Replied, post #14 · Compounds › Cagrilintide & amylin analogues · 17 Jan 2025 · 32 likes On post #10 — agreed on the reasoning, with one qualification. Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and…
  • Packaging that arrived damaged: documenting it properly Replied, post #34 · Sourcing › Logistics · 1 Jul 2026 · 31 likes At what point is a parcel genuinely a problem: if it was despatched weeks ago and there has been no update for days at customs, it might be held or lost. Days of delay…
  • Does dual agonism explain the effect size, or is it dose? Replied, post #36 · Compounds › Tirzepatide · 14 Jun 2026 · 31 likes SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose.…
  • Publishing an inconvenient result: a case study Replied, post #23 · Sourcing › Independent verification · 22 May 2025 · 31 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
  • Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly Replied, post #65 · Compounds › Tirzepatide · 20 Apr 2025 · 31 likes I read post #63 twice before replying, because I had assumed the opposite. SURMOUNT-4 used a randomised withdrawal design: everyone titrated, then those on maintenance…

Where this member posts

CategoryPostsShare
Practice2015%
Compounds2015%
Analytics1411%
Sourcing129%
Clinical118%
Outcomes86%

Badges earned, in order

BadgeTierGranted
First Replybronze1 Oct 2024
Basic Userbronze4 Oct 2024
Read the Guidelinesbronze6 Oct 2024
Welcomebronze9 Oct 2024
First Linkbronze15 Oct 2024
First Topicbronze18 Oct 2024
First Quotebronze21 Oct 2024
Editorbronze31 Oct 2024
First Tagbronze2 Nov 2024
Memberbronze5 Nov 2024
Sourcedbronze5 Dec 2024
Generousbronze21 Dec 2024
Readerbronze25 Dec 2024
First Solutionbronze11 Jan 2025
Popular Linksilver12 Jan 2025
Regularsilver13 Feb 2025
Well Sourcedsilver9 Mar 2025
Nice Postbronze28 Mar 2025
Good Postsilver5 Jun 2025
Documented a Red Flagsilver9 Jun 2025
Batch Loggersilver25 Jun 2025
Thank Yousilver23 Jul 2025
Anniversarysilver30 Sep 2025